
Aptorum Group Limited APM
$ 1.01
2.71%
Annual report 2024
added 01-17-2026
Aptorum Group Limited Depreciation & Amortization 2011-2026 | APM
Annual Depreciation & Amortization Aptorum Group Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 1.13 M | 1.21 M | 1.19 M | 1.33 M | 1.3 M | 682 K | 58.9 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.33 M | 58.9 K | 986 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Adagene
ADAG
|
723 K | $ 2.62 | 28.82 % | $ 147 M | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
28.2 M | $ 25.92 | -0.86 % | $ 1.26 B | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Ultragenyx Pharmaceutical
RARE
|
35.5 M | $ 24.45 | 4.49 % | $ 2.21 B | ||
|
Aptose Biosciences
APTO
|
32 K | - | -45.71 % | $ 1.2 M | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
Athira Pharma
ATHA
|
970 K | - | - | $ 269 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
BioXcel Therapeutics
BTAI
|
309 K | $ 1.84 | 1.66 % | $ 4.66 M | ||
|
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.66 | -1.85 % | $ 16.7 M | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
22.2 M | $ 67.49 | -3.02 % | $ 9.03 B | ||
|
Brickell Biotech
BBI
|
41 K | - | -5.38 % | $ 6.06 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
14 K | $ 4.51 | 8.41 % | $ 9.81 B | ||
|
BeiGene, Ltd.
BGNE
|
172 M | - | 0.49 % | $ 251 B | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
9.45 M | - | -15.15 % | $ 60.3 M | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 K | - | -9.72 % | $ 5.89 M | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
398 K | - | 4.14 % | $ 49.1 M | ||
|
Coherus BioSciences
CHRS
|
3.2 M | $ 2.04 | 28.3 % | $ 192 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Biogen
BIIB
|
673 M | $ 171.89 | -1.1 % | $ 25 B | ||
|
Bio-Path Holdings
BPTH
|
82 K | - | - | $ 100 K | ||
|
BioVie
BIVI
|
229 K | $ 1.2 | -3.7 % | $ 1.77 M |